Biblio Discovery — Demo Discovery Service

14 hasil untuk "Alexandre Bazinet"

Menampilkan 1–14 · 0,32 detik · RSS

  1. Artikel Jurnal

    Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

    Juan Jose Rodriguez-Sevilla; Irene Ganan-Gomez; Feiyang Ma dkk.

    Nature Communications, Vol. 15 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract The molecular mechanisms of venetoclax-based therapy failure in patients with acute myeloid leukemia were recently clarified, but the mechanisms by which patients with myelodysplastic syndromes (MDS) acquire secondary resistance to venetoclax after an initial response remain to be…

  2. Artikel Jurnal

    Outcomes and genetic dynamics of acute myeloid leukemia at first relapse

    Alex Bataller; Hagop Kantarjian; Alexandre Bazinet dkk.

    Haematologica, Vol. 999 No. 1 · 2024 · Inggris · DOAJ Scopus

    Patients with relapsed acute myeloid leukemia (rAML) experience dismal outcomes. We performed a comprehensive analysis of patients with rAML to determine the genetic dynamics and survival predictive factors. We analyzed 875 patients with newly diagnosed AML who received intensive treatment (IT) or…

  3. Artikel Jurnal

    Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia

    Thura Win Htut; Jeannot Kekedjian; Nicholas Short dkk.

    Haematologica, Vol. 999 No. 1 · 2026 · Inggris · DOAJ Scopus

    Oral decitabine/cedazuridine plus venetoclax offers a fully oral regimen for older or unfit patients with acute myeloid leukemia (AML). We previously reported outcomes from a phase II study; here we present extended follow-up of the frontline cohort. In this single-center phase II study, adults…

  4. Artikel Jurnal

    Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study

    Alex Bataller; Koji Sasaki; Samuel Urrutia dkk.

    Blood Cancer Journal, Vol. 15 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Hypomethylating agents (HMA) are indicated in the treatment of higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The combination of hypomethylating agents with venetoclax (Ven) has demonstrated promising results in these diseases, although randomized…

  5. Artikel Jurnal

    Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients

    Christophe Willekens; Alexandre Bazinet; Samy Chraibi dkk.

    Blood Cancer Journal, Vol. 15 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Hypomethylating agent (HMA) plus venetoclax (VEN) regimens are standard of care in patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. While the VEN label recommends continuous 28-day cycles, shortened VEN durations may induce similar response rates and…

  6. Artikel Jurnal

    Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes

    Alexandre Bazinet; Alex Bataller; Kelly Chien dkk.

    Blood Cancer Journal, Vol. 16 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract Allogeneic stem cell transplantation (SCT) is a curative treatment in myelodysplastic syndromes (MDS). We performed a retrospective single center study of all patients with newly diagnosed higher risk (HR) MDS (IPSS-R > 3.5 points) between 2000 and 2023. We identified 2045 patients with…